MG
ALNY icon

Marex Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Marex Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$214K Sell
711
-1,289
-64% -$389K ﹤0.01% 984
2026
Q1 		$662K Buy
+2,000
New +$681K ﹤0.01% 546
2025
Q2 		– Sell
-1,173
Closed -$317K – 653
2025
Q1 		$317K Sell
1,173
-95
-7% -$24.4K 0.01% 441
2024
Q4 		$298K Buy
+1,268
New +$333K 0.01% 451
2023
Q3 		– Sell
-1,334
Closed -$253K – 217
2023
Q2 		$253K Sell
1,334
-239
-15% -$47.4K 0.05% 182
2023
Q1 		$315K Buy
1,573
+581
+59% +$122K 0.04% 198
2022
Q4 		$236K Buy
+992
New +$212K 0.03% 216

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marex Group's ALNY Position: Q2 2026 in Review

Marex Group reduced its Alnylam Pharmaceuticals (ALNY) stake by 64% in Q2 2026, selling an estimated $389K and leaving 711 shares worth $214K. The position accounts for ﹤0.01% of the portfolio, ranked #984.

Marex Group first reported a position in ALNY in Q4 2022 and has held it in 7 quarters since. The position peaked at $662K in Q1 2026. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Marex Group held 711 shares of Alnylam Pharmaceuticals worth $214K as of Q2 2026.
  • Marex Group sold 1,289 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $389K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Marex Group's portfolio in Q2 2026, its #984 holding.
  • Marex Group first reported a position in Alnylam Pharmaceuticals in Q4 2022 and has held it in 7 quarters since.
  • Marex Group's Alnylam Pharmaceuticals position peaked at $662K in Q1 2026.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.